Antimicrobial resistance is one of the most complex global health challenges today. The world has long ignored warnings that antibiotics and other medicines are losing their effectiveness after decades of overuse and misuse in human medicine, animal health and agriculture. Common illnesses like pneumonia, postoperative infections, diarrheal and sexually transmitted diseases, as well as the world’s largest infectious disease killers – tuberculosis (TB), HIV and malaria – are increasingly becoming untreatable because of the emergence and spread of drug resistance. Worsening antimicrobial resistance could have serious public health, economic and social implications. Rep. Jan Schakowsky (D-IL) and other democrats introduced legislation aimed at controlling drug prices, providing a prize for the introduction of a new antibiotic to market that provides activity against resistant infections or other key lifesaving characteristics. Strengths of prize approach to incentivizing R&D f